Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aims: Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but some patients are statin-intolerant. We examined the effects of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab on the risk of major adverse cardiovascular events according to the intensity of background statin treatment. Methods and results: The ODYSSEY OUTCOMES trial compared alirocumab with placebo in 18,924 patients with acute coronary syndrome and dyslipidaemia despite intensive or maximum-tolerated statin treatment (including no statin if intolerance was documented). The primary outcome (major adverse cardiovascular events) comprised coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina. Median follow-up was 2.8 years. Baseline statin treatment was high-intensity (88.8%), low/moderate-intensity (8.7%) or none (2.4%). Median baseline low-density lipoprotein cholesterol was 86, 89 and 139 mg/dL (P < 0.001) in these statin treatment categories, respectively. Alirocumab produced similar relative reductions in low-density lipoprotein cholesterol from baseline across statin treatment subgroups, but the mean absolute reductions differed (52.9, 56.7 and 86.1 mg/dL, respectively; P < 0.001). With placebo, the incidence of major adverse cardiovascular events was highest in the no statin subgroup (10.8%, 10.7% and 26.0% respectively). Alirocumab reduced major adverse cardiovascular events in each statin subgroup (hazard ratio 0.88, 95% confidence interval (CI) 0.80–0.96; 0.68, 0.49–0.94; and 0.65, 0.44–0.97, respectively; Pinteraction = 0.14) with a gradient of absolute risk reduction: 1.25%, 95% CI 0.34–2.16; 3.16%, 0.38–5.94; 7.97%, 0.42–15.51; Pinteraction = 0.106). Conclusions: PCSK9 inhibition with alirocumab reduces the relative risk of major adverse cardiovascular events after acute coronary syndrome irrespective of background statin treatment. However, patients on no statin are at high absolute risk for recurrent major adverse cardiovascular events; alirocumab substantially reduces that risk. PCSK9 inhibition may be an important therapeutic strategy for statin-intolerant patients with acute coronary syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statin adherence is low and variable, with 20-60% of patients not adhering to treatment.9,10”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationStatins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Self-citationSullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408
Self-citationResistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225
Self-citation
Research works printed but not linked: 10
- Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 · DOI · Paper page
- Vonbank, 2018, Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review, Eur Heart J Cardiovasc Pharmacother, 4, 230, 10.1093/ehjcvp/pvy028 · DOI
- Alonso, 2019, Diagnosis and management of statin intolerance, J Atheroscler Thromb, 26, 207, 10.5551/jat.RV17030 · DOI
- Algharably, 2017, Statin intolerance – a question of definition, Expert Opin Drug Saf, 16, 55, 10.1080/14740338.2017.1238898 · DOI
- Shin, 2014, Association between non-adherence to statin and hospitalization for cardiovascular disease and all-cause mortality in a national cohort, Int J Clin Pharmacol Ther, 52, 948, 10.5414/CP202132 · doi:10.5414/cp202132
- Nissen, 2017, Statin intolerance: an elusive but morbid disorder, J Am Coll Cardiol, 69, 1396, 10.1016/j.jacc.2017.01.019 · DOI
- Steg, 2019, Effect of alirocumab on mortality after acute coronary syndromes, Circulation, 140, 103, 10.1161/CIRCULATIONAHA.118.038840 · DOI
- Munkhaugen, Is the novel LDL-cholesterol goal <1.4 mmol/L achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?, Eur J Prev Cardiol
- Mahmood, Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: a pooled analysis from 10 ODYSSEY phase 3 studies, Eur J Prev Cardiol
- Reiner, 2016, Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – findings from the EUROASPIRE IV survey, Atherosclerosis, 246, 243, 10.1016/j.atherosclerosis.2016.01.018 · DOI · Paper page
Cited by
PCSK9 inhibition: from effectiveness to cost-effectiveness
Mercep, I., Strikic, D., Hrabac, P., Pecin, I., & Reiner, Ž. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1339487 · Cited by 31
Self-citationRakhshanda, S., Briggs, N. E., Rhee, J., Rye, K.-A., Liaw, S.-T., & Jonnagaddala, J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag175 · Cited by 6
Metadata
- Authors
- Diaz, R., Li, Q. H., Bhatt, D. L., Bittner, V. A., Baccara-Dinet, M. T., Goodman, S. G., Jukema, J. W., Kimura, T., Parkhomenko, A., Pordy, R., Reiner, Ž., Roe, M. T., Szarek, M., Tse, H.-F., White, H. D., Zahger, D., Zeiher, A. M., Schwartz, G. G., Steg, P. G., & for the ODYSSEY OUTCOMES Committees and Investigators
- Affiliations
- Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Argentina
- Regeneron Pharmaceuticals Inc., Tarrytown, USA
- Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, USA
- Division of Cardiovascular Disease, University of Alabama at Birmingham, USA
- Sanofi R&D, Montpellier, France
- Canadian VIGOUR Centre, University of Alberta, Canada
- Department of Cardiology, Leiden University Medical Center, The Netherlands
- Kyoto University, Graduate School of Medicine, Japan
- MD Strazhesko Institute of Cardiology, AMS of Ukraine, Ukraine
- University Hospital Center Zagreb, University of Zagreb, Croatia
- Duke Clinical Research Institute, Duke University Medical Center, USA
- State University of New York, Downstate School of Public Health, USA
- Queen Mary Hospital, Hong Kong, Special Administrative Region of the People's Republic of China
- Green Lane Cardiovascular Services, Auckland City Hospital, New Zealand
- Soroka University Medical Center, Ben Gurion University of the Negev, Israel
- Department of Medicine III, Goethe University, Germany
- Division of Cardiology, University of Colorado School of Medicine, USA
- Université de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and INSERM, France
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07-27
- Volume
- 28
- Issue
- 1
- Pages
- 33-43
- ISSN
- 2047-4873
- 2047-4881
- Cited by
- 47
- References
- 9
- Language
- en
- Licence
- Funders
- Sanofi and Regeneron Pharmaceuticals, Inc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. https://app.cochat.ai/papers/10.1177/2047487320941987
- The paper
- Diaz, R., Li, Q. H., Bhatt, D. L., Bittner, V. A., Baccara-Dinet, M. T., Goodman, S. G., Jukema, J. W., Kimura, T., Parkhomenko, A., Pordy, R., Reiner, Ž., Roe, M. T., Szarek, M., Tse, H.-F., White, H. D., Zahger, D., Zeiher, A. M., Schwartz, G. G., Steg, P. G., & for the ODYSSEY OUTCOMES Committees and Investigators. (2021). Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487320941987
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.